Buclizine→see antihistamines, sedating
Budesonide→see corticosteroids
Bumetanide→see loop diuretics
Bupivacaine→see anaesthetics, local
Buprenorphine→see opioids
Bupropion→seeTABLE 13p. 850 (serotonin syndrome)
▶Bupropionis predicted to increase the exposure to
anticholinesterases, centrally acting(galantamine). Monitor and
adjust dose.oStudy
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to markedly decrease the
exposure tobupropion.rStudy
▶Antiepileptics(valproate)increase the exposure tobupropion.
rStudy
▶Antifungals, azoles(isavuconazole)slightly increase the
exposure tobupropion. Adjust dose.oStudy
▶Bupropionis predicted to moderately increase the exposure to
aripiprazole. Adjustaripiprazoledose,p. 249.oStudy
▶Bupropionis predicted to markedly increase the exposure to
atomoxetine. Adjust dose.rStudy
▶Bupropionis predicted to increase the exposure tobeta
blockers, selective(metoprolol, nebivolol).oStudy
▶Bupropionis predicted to slightly increase the exposure to
darifenacin.nStudy
▶Bupropionincreases the risk of side-effects when given with
dopamine receptor agonists(amantadine).oStudy
▶Efavirenzis predicted to decrease the exposure tobupropion.
oStudy
▶Bupropionis predicted to increase the exposure toeliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶HIV-protease inhibitors(ritonavir)are predicted to decrease the
exposure tobupropion.oStudy
▶Bupropionincreases the risk of side-effects when given with
levodopa.oStudy
▶Bupropionis predicted to increase the risk of intraoperative
hypertension when given withlinezolid.rAnecdotal→Also
seeTABLE 13p. 850
▶Methylthioninium chlorideis predicted to increase the risk of
severe hypertension when given withbupropion. Avoid.
rTheoretical→Also seeTABLE 13p. 850
▶Moclobemideis predicted to increase the risk of severe
hypertension when given withbupropion. Avoid.r
Theoretical→Also seeTABLE 13p. 850
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the risk of severe hypertension when
given withbupropion. Avoid and for 14 days after stopping the
MAOI.rTheoretical→Also seeTABLE 13p. 850
▶Monoamine-oxidase B inhibitorsare predicted to increase the
risk of severe hypertension when given withbupropion. Avoid.
oTheoretical→Also seeTABLE 13p. 850
▶Bupropionis predicted to decrease the efficacy ofopioids
(codeine).oTheoretical
▶Bupropionis predicted to decrease the efficacy ofopioids
(tramadol).rStudy→Also seeTABLE 13p. 850
▶Bupropionis predicted to moderately increase the exposure to
pitolisant. Use with caution and adjust dose.oStudy
▶Rifampicinis predicted to decrease the exposure tobupropion.
oStudy
▶Bupropionis predicted to increase the exposure torisperidone.
Adjust dose.oStudy
▶Bupropionis predicted to increase the exposure toSSRIs
(dapoxetine).oTheoretical→Also seeTABLE 13p. 850
▶Bupropionis predicted to decrease the efficacy oftamoxifen.
Avoid.rStudy
▶Bupropionis predicted to increase the exposure totricyclic
antidepressants. Monitor for toxicity and adjust dose.r
Study→Also seeTABLE 13p. 850
▶Bupropionis predicted to increase the exposure to
vortioxetine. Monitor and adjust dose.oStudy→Also
seeTABLE 13p. 850
Buspirone→seeTABLE 13p. 850 (serotonin syndrome)
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure tobuspirone. Use with caution and adjust dose.
oStudy▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
tobuspirone. Use with caution and adjust dose.rStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tobuspirone. Use with
caution and adjust dose.oStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure tobuspirone. Adjust
buspironedose.rStudy
▶Antifungals, azoles(miconazole)are predicted to increase the
concentration ofbuspirone. Use with caution and adjust dose.
oTheoretical
▶Aprepitantis predicted to increase the exposure tobuspirone.
Use with caution and adjust dose.oStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tobuspirone. Use with caution and
adjust dose.oStudy
▶Cobicistatis predicted to increase the exposure tobuspirone.
Adjustbuspironedose.rStudy
▶Crizotinibis predicted to increase the exposure tobuspirone.
Use with caution and adjust dose.oStudy
▶Enzalutamideis predicted to decrease the exposure to
buspirone. Use with caution and adjust dose.rStudy
▶Grapefruit juiceincreases the exposure tobuspirone. Avoid.
nStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
tobuspirone. Adjustbuspironedose.rStudy
▶Idelalisibis predicted to increase the exposure tobuspirone.
Adjustbuspironedose.rStudy
▶Imatinibis predicted to increase the exposure tobuspirone.
Use with caution and adjust dose.oStudy
▶Buspironeis predicted to increase the risk of elevated blood
pressure when given withlinezolid. Avoid.rTheoretical→
Also seeTABLE 13p. 850
▶Macrolides(clarithromycin)are predicted to increase the
exposure tobuspirone. Adjustbuspironedose.rStudy
▶Macrolides(erythromycin)are predicted to increase the
exposure tobuspirone. Use with caution and adjust dose.
oStudy
▶Mitotaneis predicted to decrease the exposure tobuspirone.
Use with caution and adjust dose.rStudy
▶Buspironeis predicted to increase the risk of elevated blood
pressure when given withmonoamine-oxidase A and B
inhibitors, irreversible. Avoid.rAnecdotal→Also see
TABLE 13p. 850
▶Netupitantis predicted to increase the exposure tobuspirone.
Use with caution and adjust dose.oStudy
▶Nilotinibis predicted to increase the exposure tobuspirone.
Use with caution and adjust dose.oStudy
▶Rifampicinis predicted to decrease the exposure tobuspirone.
Use with caution and adjust dose.rStudy
Busulfan→see alkylating agents
Cabazitaxel→see taxanes
Cabergoline→see dopamine receptor agonists
Cabozantinib→seeTABLE 15p. 850 (myelosuppression),TABLE 9
p. 849 (QT-interval prolongation)
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure tocabozantinib.oTheoretical→Also seeTABLE 9
p. 849
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)moderately decrease the exposure to
cabozantinib. Avoid.oStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tocabozantinib.
oTheoretical→Also seeTABLE 9p. 849
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)
slightly increase the exposure tocabozantinib.o
Study→Also seeTABLE 9p. 849
▶Aprepitantis predicted to increase the exposure to
cabozantinib.oTheoretical
▶Bosentanis predicted to decrease the exposure to
cabozantinib.oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tocabozantinib.oTheoretical888 Buclizine—Cabozantinib BNFC 2018 – 2019
Interactions|Appendix 1A1